Author |
Title |
JournalName |
Year D |
Click on Column Headers to Re-Sort The Current List |
Nichols DE |
Differences between the mechanism of action of MDMA, MBDB, and the cla... |
J Psychoactive Drugs |
1986 |
Nichols DE, Hoffman AJ, O... |
Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives ... |
J Med Chem |
1986 |
Oberlender R, Nichols DE |
Drug discrimination studies with MDMA and amphetamine |
Psychopharmacology (... |
1988 |
Nichols DE, Oberlender R |
Structure-activity relationships of MDMA and related compounds: a new ... |
Ann N Y Acad Sci |
1990 |
Oberlender R, Nichols DE |
(+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative... |
J Pharmacol Exp Ther |
1990 |
Noggle FT Jr, Clark CR, A... |
Methods for the analysis of 1-(3,4-methylenedioxyphenyl)-2-butanamine ... |
J Chromatogr Sci |
1991 |
Paulus MP, Geyer MA |
The effects of MDMA and other methylenedioxy-substituted phenylalkylam... |
Neuropsychopharmacol... |
1992 |
Hermle L, Spitzer M, Borc... |
Psychological effects of MDE in normal subjects. Are entactogens a new... |
Neuropsychopharmacol... |
1993 |
Hermle L, Spitzer M, Borc... |
Psychological effects of MDE in normal subjects. Are entactogens a new... |
Neuropsychopharmacol... |
1993 |
Cozzi NV |
PHARMACOLOGICAL STUDIES OF SOME PSYCHOACTIVE PHENYLALKYLAMINES:ENTACTO... |
|
1994 |
Hegadoren KM, Martin-Iver... |
Comparative behavioural and neurochemical studies with a psychomotor s... |
Psychopharmacology (... |
1995 |
Vollenweider FX, Gamma A,... |
Psychological and cardiovascular effects and short-term sequelae of MD... |
Neuropsychopharmacol... |
1998 |
Kovar KA |
Chemistry and pharmacology of hallucinogens, entactogens and stimulant... |
Pharmacopsychiatry |
1998 |
Schwab M, Seyringer E, Br... |
Fatal MDMA intoxication |
Lancet |
1999 |
Gouzoulis-Mayfrank E, The... |
Psychopathological, neuroendocrine and autonomic effects of 3,4-methyl... |
Psychopharmacology (... |
1999 |
Gouzoulis-Mayfrank E, Sch... |
Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetami... |
Neuropsychopharmacol... |
1999 |
Gouzoulis-Mayfrank E, Sch... |
Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetami... |
Neuropsychopharmacol... |
1999 |
van Aerts LAGJM, Malleret... |
N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB): its properties ... |
Addiction Biology |
2000 |
Vollenweider FX |
Brain mechanisms of hallucinogens and entactogens |
Dialogues Clin Neuro... |
2001 |
Harris DS, Baggott M, Men... |
Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (... |
Psychopharmacology (... |
2002 |
Riba J, Rodriguez-Fornel... |
Effects of ayahuasca on sensory and sensorimotor gating in humans as m... |
Psychopharmacology (... |
2002 |
Cole JC, Sumnall HR |
The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamp... |
Neurosci Biobehav Re... |
2003 |
Caudevilla-Galligo F, Rib... |
4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreation... |
J Psychopharmacol |
2012 |
Passie T, Benzenhöfer U |
The History of MDMA as an Underground Drug in the United States, 1960-... |
J Psychoactive Drugs |
2016 |
Pálenícek T, Lhotková E, ... |
Emerging toxicity of 5,6-methylenedioxy-2-aminoindane (MDAI): Pharmaco... |
Prog Neuropsychophar... |
2016 |
Passie T, Brandt SD |
Self-Experiments with Psychoactive Substances: A Historical Perspectiv... |
Handb Exp Pharmacol |
2018 |